Apitolisib T1916
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
Apitolisib, an effective, class I PI3K inhibitor for PI3K__IC50=5 nM_, PI3K__IC50=27 nM_, PI3K__IC50=7 nM_, PI3K_ _IC50=14 nM_, is used in trials study of solid cancers, breast cancer, prostate cancer, renal cell carcinoma, and endometrial carcinoma, amon
CAS nr:
1032754-93-0
Purity:
98%
Molecular Weight:
498,6
SMILES:
c12sc(CN3CCN(C(=O)[C@@H](O)C)CC3)c(C)c1nc(c1cnc(N)nc1)nc2N1CCOCC1
Formula:
C23H30N8O3S
Pathway:
PI3K/Akt/mTOR signaling,PI3K/Akt/mTOR signaling,Apoptosis
Target:
PI3K,mTOR,Apoptosis
